News from the drug front
In terms of private payers, the past year was a transitional year and gives a glimpse into the issues that private plan sponsors will face over the next five years. At a high level, the increase in overall dollars spent was relatively low at 6%, according to Canadian pharmacy benefit managers. Generics accounted for just […]
- May 28, 2010 September 13, 2019
- 00:00